Abstract
BackgroundResistance to anti-cancer therapeutics in colorectal cancer (CRC) is high. A molecular subtype of CRC, CMS4, has a high proportion of mesenchymal stromal cells (MSCs) in the tumour microenvironment (TME),1...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
